Clinical Scorecard: Temporary Flow Modulation Using Rapidly Resorbable Gelatin Microspheres in Yttrium-90 Radioembolization for Liver Cancer: A Preliminary Clinical Trial

At a Glance

Key Highlights

• The prospective SEGWAY phase II, single-arm trial investigated whether rapidly resorbable gelatin microspheres protect non-tumorous liver by temporarily modulating arterial flow during Y-90 radioembolization.
• The microspheres are physically crosslinked porcine gelatin and are designed to remain stable during delivery; in vitro, they are intended to dissolve by approximately 70% within 24 hours and resorb completely within 3 days.
• Operators selected the arteries for protection, microsphere type, and final prescribed tumor absorbed dose; the protocol did not specify a target tumor absorbed dose or non-tumorous liver dose in advance.
• The supplied excerpt describes the trial rationale and methods; it does not include clinical outcomes or quantitative dosimetric results.

Guideline-Based Recommendations

Diagnosis

• Trial eligibility required primary or secondary liver cancer diagnosed by Gd-EOB-DTPA-enhanced MRI or biopsy.

Management

• Planning included angiography and technetium-99m MAA imaging with planar imaging and SPECT/CT.
• The study used partition-model dosimetry. Operators selected the final prescribed tumor absorbed dose and arteries receiving RGM; the protocol did not specify target tumor or non-tumorous liver doses in advance.
• RGMs were selectively delivered through a 2.4-Fr microcatheter to arteries designated for protection from Y-90 microsphere delivery.

Monitoring & Follow-up

• Planning included segmentation of the whole liver, tumor, and non-tumorous liver, followed by manual rigid registration of SPECT/CT images.
• The estimated lung dose was below 30 Gy in the described planning approach.

Risks

• Permanent embolic agents can prevent later transarterial treatment of the protected territory and may compromise regional liver function through persistent hypoxia.
• Conventional gelatin sponge particles may take weeks to months to resorb, potentially causing persistent injury to treated arteries and corresponding liver parenchyma.
• Vascular invasion and biliary–enteric anastomosis were exclusion criteria because either condition may confound image-based evaluation of post-radioembolization non-tumorous liver function.

Patient & Prescribing Data

SEGWAY eligibility included adults with primary or secondary liver cancer, Child–Pugh class A, no locoregional treatment of the same hepatic lobe in the preceding year, and non-tumorous liver volume at least 50% of the Y-90 perfused liver volume. Patients with vascular invasion or biliary–enteric anastomosis were excluded.

Y-90 radioembolization used glass or resin microspheres. Operators selected microsphere type, activity per microsphere, prescribed tumor absorbed dose, and arteries for RGM protection. The protocol encouraged a tumoricidal dose but specified no target tumor absorbed dose or non-tumorous liver dose.

Clinical Best Practices

• Trial planning used angiography and technetium-99m MAA planar imaging and SPECT/CT.
• The study used partition-model dosimetry based on segmented whole-liver, tumor, and non-tumorous liver volumes.
• The excerpt states that operators could account for the RGM-protected territory in dosimetry planning; it does not provide enough detail to support a general best-practice recommendation.
• Remove the claim that untreated liver volume was required to exceed 30% of overall non-tumorous liver volume unless supported by the full source.

Related Resources & Content